Naslov
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Autori
Pagano, Livio ; Salmanton-García, Jon ; Marchesi, Francesco ; Busca, Alessandro ; Corradini, Paolo ; Hoenigl, Martin ; Klimko, Nikolai ; Koehler, Phillip ; Pagliuca, Antonio ; Passamonti, Francesco ; Verga, Luisa ; V¨išek, Benjamin ; Ilhan, Osman ; Nadali, Gianpaolo ; Weinbergerovä, Barbora ; Cördoba-Mascuñano, Raúl ; Marchetti, Monia ; Collins, Graham P. ; Farina, Francesca ; Cattaneo, Chiara ; Cabirta, Alba ; Gomes-Silva, Maria ; Itri, Federico ; van Doseum, Jaap

Kolaboracija
EPICOVIDEHA working group

Izvornik
Journal of Hematology & Oncology (1756-8722) 14 (2021), 1; 168, 15

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
COVID-19 ; pandemic ; hematological malignancies ; epidemiology ; EHA

Sažetak
Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientifc Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confrmed COVID19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non- Hodgkin lymphoma n=1084, myeloma n=684 and chronic lymphoid leukemia n=474) and myeloproliferative malignancies (mainly acute myeloid leukemia n=497 and myelodysplastic syndromes n=279). Severe/critical COVID-19 was observed in 63.8% of patients (n=2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate signifcantly decreased between the frst COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value<0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confrms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA